Ectopic lipid storage and insulin resistance: A harmful relationship

Journal of Internal Medicine

Volumn 274, Issue 1, 2013, Pages 25-40

  Boren J ^a   Taskinen, M R ^b   Olofsson, S O ^a   Levin, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Insulin resistance; Lipid droplets; Lipids; Lipotoxicity; NAFLD; Storage

Indexed keywords

GUANOSINE TRIPHOSPHATASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N ETHYLMALEIMIDE SENSITIVE FACTOR; PERILIPIN; PERILIPIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SNARE PROTEIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; ECTOPIC LIPID STORAGE; ENDOPLASMIC RETICULUM; FATTY LIVER; HEART FAILURE; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; LIPIDOSIS; LIPOLYSIS; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ALPHA-2-HS-GLYCOPROTEIN; ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HEART FAILURE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; METABOLIC DISEASES; MUSCLE, SKELETAL; MYOCARDIUM; OBESITY; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES;

EID: 84879094909     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12071     Document Type: Review

References (167)

1. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-7.
2. Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem 2012; 81: 687-714.
3. Beller M, Sztalryd C, Southall N et al. COPI complex is a regulator of lipid homeostasis. PLoS Biol 2008; 6: e292.
4. Guo Y, Walther TC, Rao M et al. Functional genomic screen reveals genes involved in lipid-droplet formation and utilization. Nature 2008; 453: 657-61.
5. Wolins NE, Skinner JR, Schoenfish MJ, Tzekov A, Bensch KG, Bickel PE. Adipocyte protein S3-12 coats nascent lipid droplets. J Biol Chem 2003; 278: 37713-21.
6. Londos C, Brasaemle DL, Gruia-Gray J et al. Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. Biochem Soc Trans 1995; 23: 611-5.
7. Lu X, Gruia-Gray J, Copeland NG et al. The murine perilipin gene: the lipid droplet-associated perilipins derive from tissue-specific, mRNA splice variants and define a gene family of ancient origin. Mamm Genome 2001; 12: 741-9.
8. Londos C, Brasaemle DL, Schultz CJ, Segrest JP, Kimmel AR. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol 1999; 10: 51-8.
9. Sztalryd C, Xu G, Dorward H et al. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol 2003; 161: 1093-103.
10. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 1997; 38: 2249-63.
11. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998; 294: 309-21.
12. Imamura M, Inoguchi T, Ikuyama S et al. ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab 2002; 283: E775-83.
13. Wang SM, Hwang RD, Greenberg AS, Yeo HL. Temporal and spatial assembly of lipid droplet-associated proteins in 3T3-L1 preadipocytes. Histochem Cell Biol 2003; 120: 285-92.
14. Magnusson B, Asp L, Bostrom P et al. Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler Thromb Vasc Biol 2006; 26: 1566-71.
15. Diaz E, Pfeffer SR. TIP47: a cargo selection device for mannose 6-phosphate receptor trafficking. Cell 1998; 93: 433-43.
16. Krise JP, Sincock PM, Orsel JG, Pfeffer SR. Quantitative analysis of TIP47-receptor cytoplasmic domain interactions: implications for endosome-to-trans Golgi network trafficking. J Biol Chem 2000; 275: 25188-93.
17. Wolins NE, Rubin B, Brasaemle DL. TIP47 associates with lipid droplets. J Biol Chem 2001; 276: 5101-8.
18. Dalen KT, Schoonjans K, Ulven SM et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004; 53: 1243-52.
19. Wolins NE, Quaynor BK, Skinner JR et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 2006; 55: 3418-28.
20. Dalen KT, Dahl T, Holter E et al. LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. Biochim Biophys Acta 2007; 1771: 210-27.
21. Yamaguchi T, Matsushita S, Motojima K, Hirose F, Osumi T. MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha. J Biol Chem 2006; 281: 14232-40.
22. Ozeki S, Cheng J, Tauchi-Sato K, Hatano N, Taniguchi H, Fujimoto T. Rab18 localizes to lipid droplets and induces their close apposition to the endoplasmic reticulum-derived membrane. J Cell Sci 2005; 118: 2601-11.
23. Martin S, Driessen K, Nixon SJ, Zerial M, Parton RG. Regulated localization of Rab18 to lipid droplets: effects of lipolytic stimulation and inhibition of lipid droplet catabolism. J Biol Chem 2005; 280: 42325-35.
24. Bostrom P, Andersson L, Rutberg M et al. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol 2007; 9: 1286-93.
25. Brasaemle DL, Dolios G, Shapiro L, Wang R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J Biol Chem 2004; 279: 46835-42.
26. Stone SJ, Levin MC, Zhou P, Han J, Walther TC, Farese RV Jr. The endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated membranes and has a mitochondrial targeting signal that promotes its association with mitochondria. J Biol Chem 2009; 284: 5352-61.
27. Kuerschner L, Moessinger C, Thiele C. Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets. Traffic 2008; 9: 338-52.
28. Gong J, Sun Z, Wu L et al. Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites. J Cell Biol 2011; 195: 953-63.
29. Jambunathan S, Yin J, Khan W, Tamori Y, Puri V. FSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation. PLoS One 2011; 6: e28614.
30. Xu L, Zhou L, Li P. CIDE proteins and lipid metabolism. Arterioscler Thromb Vasc Biol 2012; 32: 1094-8.
31. Gong J, Sun Z, Li P. CIDE proteins and metabolic disorders. Curr Opin Lipidol 2009; 20: 121-6.
32. Yonezawa T, Kurata R, Kimura M, Inoko H. Which CIDE are you on? Apoptosis and energy metabolism Mol BioSyst 2011; 7: 91-100.
33. Welte MA. Proteins under new management: lipid droplets deliver. Trends Cell Biol 2007; 17: 363-9.
34. Buhman KK, Chen HC, Farese RV Jr. The enzymes of neutral lipid synthesis. J Biol Chem 2001; 276: 40369-72.
35. Walther TC, Farese RV Jr. The life of lipid droplets. Biochim Biophys Acta 2009; 1791: 459-66.
36. Beller M, Bulankina AV, Hsiao HH, Urlaub H, Jackle H, Kuhnlein RP. PERILIPIN-dependent control of lipid droplet structure and fat storage in Drosophila. Cell Metab 2010; 12: 521-32.
37. Soni KG, Mardones GA, Sougrat R, Smirnova E, Jackson CL, Bonifacino JS. Coatomer-dependent protein delivery to lipid droplets. J Cell Sci 2009; 122: 1834-41.
38. Andersson L, Bostrom P, Ericson J et al. PLD1 and ERK2 regulate cytosolic lipid droplet formation. J Cell Sci 2006; 119: 2246-57.
39. Marchesan D, Rutberg M, Andersson L et al. A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation-related protein, and vimentin in a cell-free system. J Biol Chem 2003; 278: 27293-300.
40. Kooijman EE, Chupin V, de Kruijff B, Burger KN. Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Traffic 2003; 4: 162-74.
41. Carel K, Kummer JL, Schubert C, Leitner W, Heidenreich KA, Draznin B. Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes. J Biol Chem 1996; 271: 30625-30.
42. Gross DA, Snapp EL, Silver DL. Structural insights into triglyceride storage mediated by fat storage-inducing transmembrane (FIT) protein 2. PLoS One 2010; 5: e10796.
43. Jahn R, Scheller RH. SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 2006; 7: 631-43.
44. Krahmer N, Guo Y, Wilfling F et al. Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab 2011; 14: 504-15.
45. Bostrom P, Rutberg M, Ericsson J et al. Cytosolic lipid droplets increase in size by microtubule-dependent complex formation. Arterioscler Thromb Vasc Biol 2005; 25: 1945-51.
46. Subramanian V, Rothenberg A, Gomez C et al. Perilipin A mediates the reversible binding of CGI-58 to lipid droplets in 3T3-L1 adipocytes. J Biol Chem 2004; 279: 42062-71.
47. Lass A, Zimmermann R, Haemmerle G et al. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab 2006; 3: 309-19.
48. Miyoshi H, Perfield JW II, Souza SC et al. Control of adipose triglyceride lipase action by serine 517 of perilipin A globally regulates protein kinase A-stimulated lipolysis in adipocytes. J Biol Chem 2007; 282: 996-1002.
49. Granneman JG, Moore HP, Granneman RL, Greenberg AS, Obin MS, Zhu Z. Analysis of lipolytic protein trafficking and interactions in adipocytes. J Biol Chem 2007; 282: 5726-35.
50. Martinez-Botas J, Anderson JB, Tessier D et al. Absence of perilipin results in leanness and reverses obesity in Lepr(db/db) mice. Nat Genet 2000; 26: 474-9.
51. Tansey JT, Sztalryd C, Gruia-Gray J et al. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 2001; 98: 6494-9.
52. Londos C, Sztalryd C, Tansey JT, Kimmel AR. Role of PAT proteins in lipid metabolism. Biochimie 2005; 87: 45-9.
53. Wang H, Sztalryd C. Oxidative tissue: perilipin 5 links storage with the furnace. Trends Endocrinol Metab 2011; 22: 197-203.
54. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-65.
55. Megeney LA, Elder GC, Tan MH, Bonen A. Increased glucose transport in nonexercising muscle. Am J Physiol 1992; 262: E20-6.
56. Neumann-Haefelin C, Beha A, Kuhlmann J et al. Muscle-type specific intramyocellular and hepatic lipid metabolism during starvation in wistar rats. Diabetes 2004; 53: 528-34.
57. Bosma M, Hesselink MK, Sparks LM et al. Perilipin 2 improves insulin sensitivity in skeletal muscle despite elevated intramuscular lipid levels. Diabetes 2012; 61: 2679-90.
58. Adams JM II, Pratipanawatr T, Berria R et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53: 25-31.
59. Stratford S, DeWald DB, Summers SA. Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem J 2001; 354: 359-68.
60. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23: 7794-808.
61. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002; 51: 2005-11.
62. Zhang D, Christianson J, Liu ZX et al. Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab 2010; 11: 402-11.
63. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-77.
64. Chibalin AV, Leng Y, Vieira E et al. Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance. Cell 2008; 132: 375-86.
65. Amati F, Dube JJ, Alvarez-Carnero E et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes 2011; 60: 2588-97.
66. Lee JS, Pinnamaneni SK, Eo SJ et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 2006; 100: 1467-74.
67. Newgard CB, An J, Bain JR et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-26.
68. Holland WL, Bikman BT, Wang LP et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011; 121: 1858-70.
69. Huang S, Rutkowsky JM, Snodgrass RG et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res 2012; 53: 2002-13.
70. Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 2009; 20: 379-85.
71. Koves TR, Ussher JR, Noland RC et al. Mitochondrial overload and incomplete Fatty Acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
72. Kienesberger PC, Pulinilkunnil T, Nagendran J, Dyck JR. Myocardial triacylglycerol metabolism. J Mol Cell Cardiol 2012; 55: 101-10.
73. Niu YG, Evans RD. Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes. J Physiol 2009; 587: 3301-15.
74. Lewin TM, Coleman RA. Regulation of myocardial triacylglycerol synthesis and metabolism. Biochim Biophys Acta 2003; 1634: 63-75.
75. Crass MF III. Myocardial triacylglycerol metabolism in ischemia. Tex Rep Biol Med 1979; 39: 439-52.
76. Boren J, Veniant MM, Young SG. Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 1998; 101: 1197-202.
77. Torffvit O, Agardh C. The prognosis for type 2 diabetic patients with heart disease. A 10-year observation study of 385 patients. J Diabetes Complications 2000; 14: 301-6.
78. Bilheimer DW, Buja LM, Parkey RW, Bonte FJ, Willerson JT. Fatty acid accumulation and abnormal lipid deposition in peripheral and border zones of experimental myocardial infarcts. J Nucl Med 1978; 19: 276-83.
79. Perman JC, Bostrom P, Lindbom M et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest 2011; 121: 2625-40.
80. Chokshi A, Drosatos K, Cheema FH et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012; 125: 2844-53.
81. Listenberger LL, Han X, Lewis SE et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100: 3077-82.
82. Nojiri H, Shimizu T, Funakoshi M et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 2006; 281: 33789-801.
83. Park TS, Goldberg IJ. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin 2012; 8: 633-41.
84. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab 2007; 5: 237-52.
85. Bostrom P, Andersson L, Vind B et al. The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin resistance/type 2 diabetes. Diabetes 2010; 59: 1870-8.
86. Olofsson SO, Andersson L, Haversen L et al. The formation of lipid droplets: possible role in the development of insulin resistance/type 2 diabetes. Prostaglandins Leukot Essent Fatty Acids 2011; 85: 215-8.
87. Liu L, Zhang Y, Chen N, Shi X, Tsang B, Yu YH. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 2007; 117: 1679-89.
88. Schwenk RW, Angin Y, Steinbusch LK et al. Overexpression of VAMP3, but not VAMP2, protects GLUT4 translocation in an in vitro model of cardiac insulin resistance. J Biol Chem 2012; 287: 37530-9.
89. Muoio DM. Revisiting the connection between intramyocellular lipids and insulin resistance: a long and winding road. Diabetologia 2012; 55: 2551-4.
90. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45: 42-72.
91. Reynolds CM, McGillicuddy FC, Harford KA, Finucane OM, Mills KH, Roche HM. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res 2012; 56: 1212-22.
92. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-36.
93. Boren J, Graham L, Wettesten M, Scott J, White A, Olofsson SO. The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins. J Biol Chem 1992; 267: 9858-67.
94. Stillemark-Billton P, Beck C, Boren J, Olofsson SO. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J Lipid Res 2005; 46: 104-14.
95. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012; 32: 2104-12.
96. Bostrom K, Wettesten M, Boren J, Bondjers G, Wiklund O, Olofsson SO. Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. J Biol Chem 1986; 261: 13800-6.
97. Olofsson SO, Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler Thromb Vasc Biol 2012; 32: 1334-8.
98. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277: 17377-80.
99. Fisher EA, Pan M, Chen X et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276: 27855-63.
100. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004; 113: 1277-87.
101. Brodsky JL, Fisher EA. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab 2008; 19: 254-9.
102. Fisher EA, Williams KJ. Autophagy of an oxidized, aggregated protein beyond the ER: a pathway for remarkably late-stage quality control. Autophagy 2008; 4: 721-3.
103. Wiggins D, Gibbons GF. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J 1992; 284: 457-62.
104. Salter AM, Wiggins D, Sessions VA, Gibbons GF. The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem J 1998; 332(Pt 3): 667-72.
105. Gibbons GF, Islam K, Pease RJ. Mobilisation of triacylglycerol stores. Biochim Biophys Acta 2000; 1483: 37-57.
106. Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 2010; 7: 35.
107. Olofsson S-O, Bjursell G, Boström K et al. Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis 1987; 68: 1-17.
108. Murphy DJ, Vance J. Mechanisms of lipid-body formation. Trends Biochem Sci 1999; 24: 109-15.
109. Brown DA. Lipid droplets: proteins floating on a pool of fat. Curr Biol 2001; 11: R446-9.
110. Ye J, Li JZ, Liu Y et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab 2009; 9: 177-90.
111. Adiels M, Taskinen MR, Packard C et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-65.
112. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26.
113. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
114. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982; 31: 217-25.
115. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000; 30: 685-94.
116. Ouguerram K, Magot T, Zair Y et al. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 2003; 306: 332-7.
117. Cummings MH, Watts GF, Umpleby AM et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995; 38: 959-67.
118. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
119. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006; 14(Suppl 1): 41S-9S.
120. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17: 238-46.
121. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J Biol Chem 1999; 274: 27793-800.
122. Yao Z, Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol 2012; 23: 206-12.
123. Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol 2009; 20: 217-26.
124. Sparks JD, Sparks CE. Overindulgence and metabolic syndrome: is FoxO1 a missing link? J Clin Invest 2008; 118: 2012-5.
125. Malmstrom R, Packard CJ, Watson TD et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17: 1454-64.
126. Malmstrom R, Packard CJ, Caslake M et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998; 47: 779-87.
127. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993; 42: 833-42.
128. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95: 158-66.
129. Adiels M, Westerbacka J, Soro-Paavonen A et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007; 50: 2356-65.
130. Adiels M, Packard C, Caslake MJ et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 2005; 46: 58-67.
131. Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr DiabRep 2008; 8: 60-4.
132. Adiels M, Westerbacka J, Soro-Paavonen A et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007; 50: 2356-65.
133. Sparks JD, Sparks CE. Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion. Biochem Biophys Res Commun 1994; 205: 417-22.
134. Wiegman CH, Bandsma RH, Ouwens M et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 2003; 52: 1081-9.
135. Sorensen LP, Sondergaard E, Nellemann B, Christiansen JS, Gormsen LC, Nielsen S. Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men. Diabetes 2011; 60: 2257-64.
136. Barrows BR, Parks EJ. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 2006; 91: 1446-52.
137. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
138. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 2005; 81: 35-42.
139. Caron S, Verrijken A, Mertens I et al. Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. Arterioscler Thromb Vasc Biol 2010; 31: 513-9.
140. Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res 2011; 108: 727-42.
141. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem 1997; 272: 30693-702.
142. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215: 9-32.
143. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J 1996; 313(Pt 2): 567-74.
144. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
145. Taghibiglou C, Carpentier A, Van Iderstine SC et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275: 8416-25.
146. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002; 277: 793-803.
147. Agouni A, Mody N, Owen C et al. Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem J 2011; 438: 369-78.
148. Delibegovic M, Zimmer D, Kauffman C et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 2009; 58: 590-9.
149. Qiu W, Federico L, Naples M et al. Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. Hepatology 2008; 48: 1799-809.
150. Au CS, Wagner A, Chong T, Qiu W, Sparks JD, Adeli K. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha. Metabolism 2004; 53: 228-35.
151. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005; 54: 1676-83.
152. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004; 432: 1027-32.
153. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006; 3: 99-110.
154. Wu X, Williams KJ. NOX4 pathway as a source of selective insulin resistance and responsiveness. Arterioscler Thromb Vasc Biol 2012; 32: 1236-45.
155. Wu X, Chen K, Williams KJ. The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. Curr Opin Lipidol 2012; 23: 334-44.
156. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-7.
157. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 2012; 249: 218-38.
158. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012; 8: 709-16.
159. Dali-Youcef N, Mecili M, Ricci R, Andres E. Metabolic inflammation: connecting obesity and insulin resistance. Ann Med 2012; [Epub ahead of print].
160. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32: 1771-6.
161. Huang W, Metlakunta A, Dedousis N et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010; 59: 347-57.
162. Qin B, Anderson RA, Adeli K. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1120-9.
163. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract 2010; 2010: 11 pp.
164. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-25.
165. Heinrichsdorff J, Olefsky JM. Fetuin-A: the missing link in lipid-induced inflammation. Nat Med 2012; 18: 1182-3.
166. Pal D, Dasgupta S, Kundu R et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; doi: 10.1038/nm.2851. [Epub ahead of print].
167. Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 2013; 62: 49-55.